Loading
Cumulus Neuroscience
Cumulus Neuroscience is a neurotechnology and biotechnology company based in Belfast, Northern Ireland, founded in 2015. The company specializes in developing the NeuLogiq® platform, an AI-powered digital biomarker system designed to enhance clinical trials for central nervous system (CNS) disorders. NeuLogiq® captures real-world clinical trial data outside of traditional clinical settings, facilitating faster and more efficient drug development. The platform features a medical-grade EEG headset that allows patients to monitor brain function at home, along with AI-driven analytics to assess cognitive, mood, and language-related biomarkers. Cumulus Neuroscience serves pharmaceutical companies, biotech firms, and academic researchers, providing them with objective measures of brain function to evaluate drug effects and disease progression. The company has established partnerships with leading pharmaceutical companies and has received funding from various financial partners to support its mission of improving the diagnosis and management of CNS disorders globally.
Funding
Every round, secondary, debt facility or acquisition involving Cumulus Neuroscience that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$7M